Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
All content for Can We End Epidemics? is the property of Foreign Policy and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
To deliver the choice in quality care that people deserve, expanding the pipeline of options required to diagnose, test, prevent, treat, and eventually cure HIV and end the AIDS epidemic is critical. Host Henry Bonsu is joined by AVAC’s Executive Director Mitchell Warren and Dr. Kimberly Smith, Senior VP and Head of Research and Development ViiV Healthcare to discuss advances in HIV and infectious disease science including for sexual and reproductive health more broadly, we learn more about what promises the future might offer and what are some of the pitfalls we need to overcome?
Glossary of terms used this season: https://foreignpolicy.com/podcasts/can-we-end-epidemics/
Can We End Epidemics?
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
